Europe’s deeptech machine is becoming institutionalised
Paris-based venture capital firm Elaia has closed its third dedicated deeptech seed vehicle, DTS3, at €134 million, roughly doubling the size of its earlier deeptech seed funds. The fund will back pre-seed and seed-stage European startups in computing, life sciences and industrial innovation, with a strong emphasis on companies emerging from leading research institutions.
The significance extends beyond the size of the fund. Europe has long produced world-class research in quantum systems, biotechnology, advanced materials and industrial science. The challenge has been commercial translation: too many discoveries remained inside laboratories, grant programmes or technology transfer offices without a reliable path into venture-scale businesses.
Elaia’s latest vehicle reflects how that gap is beginning to close.
Two decades of deeptech investing experience
The story is also about Elaia’s own evolution as a European venture firm.
Founded in 2002 in Paris by Xavier Lazarus, Elaia first built its reputation through software and digital economy investments before expanding into deeptech, biotech and frontier industrial technologies. Over more than two decades, it has grown into one of Europe’s most established specialist technology investors, managing around €1 billion in assets and investing from pre-seed through Series B.
Its historical track record includes backing companies such as Criteo, Mirakl, Shift Technology, Aqemia and Alice & Bob. That breadth matters. It shows a venture model that has evolved across multiple technology cycles, from enterprise software to quantum computing and AI-native drug discovery.
The new fund is therefore best understood as the continuation of a long-running thesis: Europe’s scientific strength requires specialised capital and a deliberate bridge from lab to market.
Elaia’s institutional edge
A defining feature of Elaia’s deeptech strategy is its proximity to Europe’s research ecosystem.
DTS3 has been developed alongside institutions including PSL, Inria, CNRS, the Barcelona Supercomputing Centre and the Max Planck Foundation. Rather than waiting for founders to arrive with polished investor decks, Elaia is positioned closer to the origin point of frontier science.
This creates a structural advantage.
The firm gains earlier visibility into breakthrough intellectual property, founding teams and scientific platforms before they are fully shaped into venture-backed companies. That approach has already helped produce companies such as Aqemia, Alice & Bob and Mablink Bioscience.
This is what makes Elaia unique in the European deeptech market: its moat is not capital alone, but institutional access, technical diligence and spinout formation expertise.
A sign of Europe’s ecosystem maturity
The scale of the fund also points to broader maturity in the European deeptech ecosystem.
Elaia plans to invest between €1 million and €13 million per company, targeting around 40 startups across Europe. The first investments already span France, Germany, Switzerland, Spain and the UK.
A seed vehicle of this size only works when several parts of the ecosystem are strengthening at the same time:
- research is becoming more venture-ready
- founding teams are more commercially experienced
- industrial customers are engaging earlier
- follow-on capital is increasingly available
Europe’s scale-up gap has not disappeared, particularly at later stages where US capital remains dominant. Yet the rise of larger specialist seed funds suggests the science-to-company pipeline is becoming materially stronger.
More than a venture capital story
What emerges here is something larger than a fund close.
Elaia increasingly represents a new class of investor in Europe: firms that operate as part of the continent’s science commercialisation infrastructure.
The distinction matters for founders, universities and business leaders alike.
Tomorrow’s health platforms, industrial systems, climate technologies and strategic infrastructure companies will increasingly emerge from these structured pipelines linking research institutions, venture capital and industrial customers.
For universities and students, this creates a clearer route from scientific impact to company creation. For corporate leaders, it offers earlier access to breakthrough technologies being built inside Europe’s leading labs.
The next European challenge
The broader question now is whether this model remains concentrated around already dominant clusters.
Paris, Zurich, Munich, Cambridge and Lausanne are highly investable research hubs. The next phase of Europe’s deeptech economy will depend on whether regional centres such as Eindhoven, Twente, Leuven and Grenoble can access the same quality of specialist early-stage capital.
The long-term strength of Europe’s innovation economy depends not only on larger funds, but on whether distributed scientific excellence can become equally investable.
That is the real significance of Elaia’s €134 million fund.
It is not simply more money entering deeptech. It is further evidence that Europe is building a repeatable operating system for turning frontier science into globally relevant companies.
Further reading on MoveTheNeedle.news:
What if Europe’s fragmented deeptech ecosystem is actually an advantage?
Kembara’s €750M first close puts Europe’s deep-tech scale-up gap back under the microscope
Liked this article? Support our independent journalism on: